Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Novo Nordisk has ushered in a new era of obesity treatment – gaining the first US Food and Drug Administration (FDA) approval ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...

A pill version of weight-loss drug Wegovy will be manufactured in the Triangle and could be available within weeks after the ...

The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

US regulators approved a pill form of the obesity drug Wegovy. The injectable forms have revolutionized weight loss treatment ...